In keeping with high Survivin expression, SurVaxM, an immunogenic modified version of Survivin, has been used to vaccinate against GL261 murine GBM, producing potent CD8+ T-cell responses and significantly improved overall mouse survival [459]. Here, BIRC5 is linked to glioblastoma.